Sign In
Last checked at 
22 May 2014 09:22
Oxford BioMedica Director Declaration
Oxford, UK - 22 May 2014: Oxford BioMedica plc (LSE: OXB), ("the Company") the leading gene based biopharmaceutical company, today announces that, in accordance with LR 9.6.14 R, it has been informed that John Dawson, Chief Executive Officer of the Company, has been appointed Non-Executive Director of PAION AG.
-Ends-
For further information, please contact: |
|
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer | Tel: +44 (0)1865 783 000 |
Media Enquiries: Mary-Jane Elliott/Emma Thompson/Jessica Hodgson/ Matthew Neal Consilium Strategic Communications
|
Tel: +44 (0)20 3709 5700
|
Notes for editors
About Oxford BioMedica®
Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad range of partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.
Follow the stocks
